{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:35:11Z","timestamp":1777386911593,"version":"3.51.4"},"reference-count":36,"publisher":"American Diabetes Association","issue":"1","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,1,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of basal insulin peglispro (BIL) versus insulin glargine in patients with type 2 diabetes (hemoglobin A1c [HbA1c] \u22649% [75 mmol\/mol]) treated with basal insulin alone or with three or fewer oral antihyperglycemic medications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>This 52-week, open-label, treat-to-target study randomized patients (mean HbA1c 7.42% [57.6 mmol\/mol]) to BIL (n = 307) or glargine (n = 159). The primary end point was change from baseline HbA1c to 26 weeks (0.4% [4.4 mmol\/mol] noninferiority margin).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>At 26 weeks, reduction in HbA1c was superior with BIL versus glargine (\u22120.82% [\u22128.9 mmol\/mol] vs. \u22120.29% [\u22123.2 mmol\/mol]; least squares mean difference \u22120.52%, 95% CI \u22120.67 to \u22120.38 [\u22125.7 mmol\/mol, 95% CI \u22127.3 to \u22124.2; P &amp;lt; 0.001); greater reduction in HbA1c with BIL was maintained at 52 weeks. More BIL patients achieved HbA1c &amp;lt;7% (53 mmol\/mol) at weeks 26 and 52 (P &amp;lt; 0.001). With BIL versus glargine, nocturnal hypoglycemia rate was 60% lower, more patients achieved HbA1c &amp;lt;7% (53 mmol\/mol) without nocturnal hypoglycemia at 26 and 52 weeks (P &amp;lt; 0.001), and total hypoglycemia rates were lower at 52 weeks (P = 0.03). At weeks 26 and 52, glucose variability was lower (P &amp;lt; 0.01), basal insulin dose was higher (P &amp;lt; 0.001), and triglycerides and aminotransferases were higher with BIL versus glargine (P &amp;lt; 0.05). Liver fat content (LFC), assessed in a subset of patients (n = 162), increased from baseline with BIL versus glargine (P &amp;lt; 0.001), with stable levels between 26 and 52 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>BIL provided superior glycemic control versus glargine, with reduced nocturnal and total hypoglycemia, lower glucose variability, and increased triglycerides, aminotransferases, and LFC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc15-1531","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T02:49:24Z","timestamp":1447814964000},"page":"92-100","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":64,"title":["Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5"],"prefix":"10.2337","volume":"39","author":[{"given":"John B.","family":"Buse","sequence":"first","affiliation":[{"name":"University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena W.","family":"Rodbard","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Consultants, Rockville, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Trescoli Serrano","sequence":"additional","affiliation":[{"name":"Hospital de la Ribera, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junxiang","family":"Luo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor","family":"Ivanyi","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Bue-Valleskey","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark L.","family":"Hartman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Carey","sequence":"additional","affiliation":[{"name":"inVentiv Health Clinical, Blue Bell, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette M.","family":"Chang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2015,11,17]]},"reference":[{"key":"2022031221022804000_B1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/dmrr.733","article-title":"When basal insulin therapy in type 2 diabetes mellitus is not enough--what next","volume":"23","author":"Raccah","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031221022804000_B2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2011.621416","article-title":"Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes","volume":"27","author":"Ross","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"2022031221022804000_B3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/dom.12072","article-title":"Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus","volume":"15","author":"Karl","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022031221022804000_B4","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.2337\/dc09-S318","article-title":"Insulin therapy for type 2 diabetes","volume":"32","author":"Swinnen","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031221022804000_B5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/dom.12222","article-title":"Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus","volume":"16","author":"Sinha","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031221022804000_B6","first-page":"A226","article-title":"Basal insulin peglispro demonstrates preferential hepatic vs. peripheral action relative to insulin glargine in healthy subjects","volume":"63","author":"Henry","year":"2014","journal-title":"Diabetes"},{"key":"2022031221022804000_B7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2337\/db13-0826","article-title":"Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism","volume":"63","author":"Moore","year":"2014","journal-title":"Diabetes"},{"key":"2022031221022804000_B8","first-page":"S1","article-title":"Basal insulin peglispro (BIL) demonstrates hepato-preferential action vs. insulin glargine (GL) in patients with type 1 diabetes mellitus","volume":"58","author":"Mudaliar","year":"2015","journal-title":"Diabetologia"},{"key":"2022031221022804000_B9","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jcem-56-6-1294","article-title":"Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion","volume":"56","author":"Eaton","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221022804000_B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/dom.12117","article-title":"Hepatoselectivity and the evolution of insulin","volume":"16","author":"Herring","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031221022804000_B11","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.2337\/dc12-0060","article-title":"A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes","volume":"35","author":"Bergenstal","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031221022804000_B12","unstructured":"World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia [Internet], 2006. Available from http:\/\/www.who.int\/diabetes\/publications\/Definition%20and%20diagnosis%20of%20diabetes_new.pdf. Accessed 27 October 2014"},{"key":"2022031221022804000_B13","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/jmri.23928","article-title":"Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging","volume":"37","author":"Mashhood","year":"2013","journal-title":"J Magn Reson Imaging"},{"key":"2022031221022804000_B14","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/sim.3307","article-title":"A note on tree gatekeeping procedures in clinical trials","volume":"27","author":"Dmitrienko","year":"2008","journal-title":"Stat Med"},{"key":"2022031221022804000_B15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/pst.1576","article-title":"Analysis of hypoglycemic events using negative binomial models","volume":"12","author":"Luo","year":"2013","journal-title":"Pharm Stat"},{"key":"2022031221022804000_B16","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00125-007-0911-x","article-title":"A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"51","author":"Rosenstock","year":"2008","journal-title":"Diabetologia"},{"key":"2022031221022804000_B17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13300-014-0076-9","article-title":"Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials","volume":"5","author":"Vora","year":"2014","journal-title":"Diabetes Ther"},{"key":"2022031221022804000_B18","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.clinthera.2008.11.001","article-title":"A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes","volume":"30","author":"Hollander","year":"2008","journal-title":"Clin Ther"},{"key":"2022031221022804000_B19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"key":"2022031221022804000_B20","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031221022804000_B21","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031221022804000_B22","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/dmrr.989","article-title":"Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes","volume":"25","author":"Raskin","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031221022804000_B23","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031221022804000_B24"},{"key":"2022031221022804000_B25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2337\/dc12-0067","article-title":"Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031221022804000_B26","first-page":"A233","article-title":"LY2605541 (LY) exhibits a flatter glucodynamic profile than insulin glargine (GL) at steady state in subjects with type 1 diabetes (T1D)","volume":"62","author":"Morrow","year":"2013","journal-title":"Diabetes"},{"key":"2022031221022804000_B27","unstructured":"U.S. Food and Drug Administration. Guidance for industry drug-induced liver injury: premarketing clinical evaluation [Internet], 2009. Available from http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM174090.pdf. Accessed 22 September 2014"},{"key":"2022031221022804000_B28","doi-asserted-by":"crossref","first-page":"E829","DOI":"10.1152\/ajpendo.00133.2006","article-title":"Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes","volume":"292","author":"Juurinen","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031221022804000_B29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jdiacomp.2007.02.005","article-title":"Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes","volume":"21","author":"Lingvay","year":"2007","journal-title":"J Diabetes Complications"},{"key":"2022031221022804000_B30","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1073\/pnas.1423952112","article-title":"Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids","volume":"112","author":"Vatner","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022031221022804000_B31","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/dmrr.1305","article-title":"Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis","volume":"28","author":"Chaudhuri","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031221022804000_B32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1464-5491.2006.01881.x","article-title":"A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and\/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study","volume":"23","author":"Gerstein","year":"2006","journal-title":"Diabet Med"},{"key":"2022031221022804000_B33","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","article-title":"Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study","volume":"49","author":"Yki-J\u00e4rvinen","year":"2006","journal-title":"Diabetologia"},{"key":"2022031221022804000_B34","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.atherosclerosis.2012.07.042","article-title":"Fatty liver, abdominal adipose tissue and atherosclerotic calcification in African Americans: the Jackson Heart Study","volume":"224","author":"Liu","year":"2012","journal-title":"Atherosclerosis"},{"key":"2022031221022804000_B35","first-page":"A250","article-title":"Superior HbA1c reduction with basal insulin peglispro (BIL) vs insulin glargine (GL) and preprandial insulin lispro in a double-blind study in patients (pts) with type 2 diabetes (T2D): IMAGINE 4","volume":"64","author":"Blevins","year":"2015","journal-title":"Diabetes"},{"key":"2022031221022804000_B36"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/1\/92\/624487\/dc151531.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/1\/92\/624487\/dc151531.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T23:07:44Z","timestamp":1647126464000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/39\/1\/92\/31362\/Randomized-Clinical-Trial-Comparing-Basal-Insulin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,17]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,11,17]]},"published-print":{"date-parts":[[2016,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc15-1531","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,17]]}}}